Changes in platelet size induced by treatment in patients with Myeloproliferative Neoplasms. Cytoskeletal study during platelet production.

CELLUCI MS.; LEV PR.; YAÑUK D.; GOETTE NP.; GLEMBOTSKY AC.; DE LUCA G.; LIRA MC; BARONI PIETTO MC; HELLER PG.; MARTA RF.

Congreso; ISTH 2023 Congress of the International Society on Thrombosis and Haemostasis (ISTH), Montreal, Canada, 24-28 de Junio 2023; 2023

Hydroxyurea (HU), α-Interferon (α-IFN), anagrelide (ANA) and ruxolitinib (Ruxo) are used in MPN treatment, conditions associated to thrombosis. Considering that large platelets could be related to thrombotic events, Maximum Platelet Diameter (MPD) was evaluated in blood smears from 76 MPN patients (table1). Increased MPD was found in patients treated with αIFN, ANA and Ruxo compared to controls (n=37) and HU (p